Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - What's Next?

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report)'s share price gapped up prior to trading on Tuesday . The stock had previously closed at $21.05, but opened at $21.68. Structure Therapeutics shares last traded at $20.36, with a volume of 67,221 shares changing hands.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reaffirmed a "market outperform" rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, William Blair initiated coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $81.29.

Structure Therapeutics Stock Performance

The stock has a fifty day simple moving average of $24.19 and a two-hundred day simple moving average of $31.24. The stock has a market cap of $1.13 billion, a PE ratio of -26.72 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, equities analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Remove Ads

Institutional Trading of Structure Therapeutics

Several large investors have recently modified their holdings of GPCR. Deep Track Capital LP boosted its holdings in Structure Therapeutics by 129.4% in the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock valued at $75,936,000 after purchasing an additional 1,579,492 shares during the last quarter. Point72 Asset Management L.P. boosted its stake in shares of Structure Therapeutics by 196.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company's stock valued at $54,348,000 after buying an additional 820,589 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Structure Therapeutics by 18.0% during the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company's stock worth $173,623,000 after buying an additional 602,609 shares in the last quarter. Vestal Point Capital LP boosted its stake in Structure Therapeutics by 105.4% during the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company's stock valued at $50,474,000 after acquiring an additional 590,000 shares during the last quarter. Finally, Boxer Capital Management LLC bought a new position in shares of Structure Therapeutics during the fourth quarter worth about $13,560,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.